| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Collaboration will leverage AI-powered neural analysis and Compass' expertise in psychedelic drug development to advance new therapies for mental health
NeuroKaire, a pioneer in precision psychiatry and neurology, has launched an R&D collaboration with Compass Pathways, a leading biotechnology company dedicated to transforming mental health care.
This collaboration aims to deepen the mechanistic understanding of psychedelic compounds by testing the structure of, and connectivity between neurons (brain cells) using patient-derived neurons with known clinical phenotypes. The study will make use of stem cell derived-neurons from individuals with treatment-resistant depression (TRD) and major depressive disorder (MDD).
The planned study leverages NeuroKaire's proprietary platform, which applies cutting edge biology and AI-powered image analysis to see how various compounds affect aspects of communication between the neurons using a proprietary neuroplasticity marker. This provides a unique window into the cellular mechanisms of these potential treatments, and to the differences between them.
This collaboration brings NeuroKaire together with a true global innovator. Compass Pathways is at the forefront of mental health innovation, committed to rigorous science and accelerating patient access to new evidence-based treatments.
Dr. Daphna Laifenfeld, Co-founder and CSO of NeuroKaire, described Compass as a "true innovator" and expressed excitement about unlocking new insights that could support the development of more effective, personalized treatments.
Posted In: CMPS
